Novavax Says Is Not Expecting Authorization Of Its Updated Covid-19 Vaccine Before CDC Advisors Meet On Tuesday
Portfolio Pulse from Benzinga Newsdesk
Novavax has announced that it does not expect its updated Covid-19 vaccine to be authorized before the CDC advisors meet on Tuesday, according to Reuters.
September 11, 2023 | 6:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novavax's announcement about the delay in authorization of its updated Covid-19 vaccine may impact its stock negatively in the short term.
Novavax's updated Covid-19 vaccine is a significant part of its product portfolio. Any delay in its authorization can be seen as a setback, potentially leading to a negative impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100